At what infusion rate should 2 mg of magnesium be administered intravenously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Magnesium 2 g Infusion Rate

Administer 2 g of magnesium sulfate intravenously over 15 minutes for most acute indications, including torsades de pointes and polymorphic ventricular tachycardia with QT prolongation. 1

Evidence-Based Infusion Rates by Clinical Context

Cardiac Arrhythmias (Torsades de Pointes)

The 2010 AHA ACLS Guidelines establish the standard for magnesium administration in life-threatening arrhythmias:

  • 1 to 2 g IV over 15 minutes for polymorphic VT associated with QT prolongation (torsades de pointes) 1
  • For pulseless torsades, give as a bolus 2
  • For torsades with pulses, infuse over 10-20 minutes 2

The 2004 ACC/AHA STEMI Guidelines similarly recommend 1 to 2 g as an intravenous bolus over 5 minutes for torsades-type VT 3. The 2010 AHA statement on torsades prevention specifies 2 g can be infused intravenously and may require repeated doses 4.

Hypomagnesemia in Pediatrics

For pediatric patients with hypomagnesemia or torsades:

  • 25-50 mg/kg (maximum 2 g) over 10-20 minutes for hypomagnesemia/torsades with pulses 2
  • Over 15-30 minutes for refractory status asthmaticus 2

FDA-Approved Labeling

The FDA label provides general guidance that the rate of IV injection should generally not exceed 150 mg/minute (1.5 mL of a 10% concentration), except in severe eclampsia with seizures 5. This translates to approximately 13-14 minutes for a 2 g dose under routine circumstances.

Clinical Rationale

Rapid infusion may cause hypotension and bradycardia 2, which is why the 15-minute timeframe represents a balance between therapeutic urgency and safety. The mechanism involves:

  • Vasodilation leading to hypotension
  • Direct effects on cardiac conduction
  • CNS toxicity and respiratory depression at toxic levels 1

Have calcium chloride available to reverse magnesium toxicity if needed 2.

Context-Specific Modifications

When to Infuse More Slowly

  • Hypomagnesemia without arrhythmia: Consider slower infusion over 10-20 minutes 2
  • Renal insufficiency: Exercise greater caution; monitor serum levels closely 1
  • Hemodynamically unstable patients: Balance speed against risk of further hypotension

When Bolus Administration is Appropriate

  • Cardiac arrest with pulseless torsades: Give as rapid IV/IO bolus 2, 1
  • Severe eclampsia with active seizures: May exceed standard rate per FDA labeling 5

Safety Monitoring

During and immediately after infusion, monitor:

  • Blood pressure (watch for hypotension)
  • Heart rate (watch for bradycardia)
  • Respiratory rate (depression occurs at high serum levels)
  • Deep tendon reflexes (loss indicates impending toxicity at 3.5-5 mmol/L)

Therapeutic range: 1.8-3.0 mmol/L for eclamptic convulsions 6
Toxicity warning signs: Loss of patellar reflex (3.5-5 mmol/L), respiratory paralysis (5-6.5 mmol/L), cardiac arrest (>12.5 mmol/L) 6

Common Pitfalls

  1. Infusing too slowly in emergent arrhythmias: The 15-minute standard exists for a reason—slower infusion may delay therapeutic effect when treating life-threatening torsades
  2. Forgetting to dilute: Solutions for IV infusion must be diluted to 20% concentration or less 5
  3. Inadequate monitoring: Hypotension and bradycardia can develop during infusion; continuous monitoring is essential
  4. Ignoring renal function: Magnesium is renally excreted; adjust dosing and increase monitoring frequency in renal insufficiency 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.